Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.07 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.22M shares, a 21.51% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.85M shares, a 495.15% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 633.97K shares, a 57.02% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.67M shares, a 82.41% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.78M shares, a 4.97% increase from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.60M shares, a 113.57% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.69M shares, a 25.50% decline from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.27M shares, a 1.09% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 1.22M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | 4.07M shares 10-Q · filed 2026-07-29 | 4.71M shares derived: sum of 3 quarters · filed 2026-07-29 | 6.37M shares derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | 2.85M shares 10-Q · filed 2026-05-11 | 3.49M shares derived: sum of 2 quarters · filed 2026-05-11 | 5.15M shares derived: sum of 3 quarters · filed 2026-05-11 | 6.16M shares derived: sum of 4 quarters · filed 2026-05-11 | |
| 2025-12-31 | 633.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 2.30M shares derived: sum of 2 quarters · filed 2026-03-02 | 3.30M shares derived: sum of 3 quarters · filed 2026-03-02 | 3.78M shares 10-K · filed 2026-03-02 | |
| 2025-09-30 | 1.67M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 2.67M shares derived: sum of 2 quarters · filed 2025-11-05 | 3.15M shares 10-Q · filed 2025-11-05 | 4.62M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-07-31 | 591.68K shares 10-K · filed 2026-03-02 | ||||
| 2025-06-30 | 1.00M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | 1.48M shares 10-Q · filed 2025-07-28 | 2.96M shares derived: sum of 3 quarters · filed 2025-07-28 | 3.87M shares derived: sum of 4 quarters · filed 2025-07-28 | |
| 2025-03-31 | 479.30K shares 10-Q · filed 2025-05-08 | 1.95M shares derived: sum of 2 quarters · filed 2025-05-08 | 2.87M shares derived: sum of 3 quarters · filed 2025-05-08 | 3.23M shares derived: sum of 4 quarters · filed 2025-05-08 | |
| 2024-12-31 | 1.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 2.39M shares derived: sum of 2 quarters · filed 2025-02-27 | 2.75M shares derived: sum of 3 quarters · filed 2025-02-27 | 3.60M shares 10-K · filed 2025-02-27 | |
| 2024-09-30 | 913.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 1.28M shares derived: sum of 2 quarters · filed 2024-11-12 | 2.13M shares 10-Q · filed 2024-11-12 | 3.05M shares derived: sum of 4 quarters · filed 2024-11-12 | |
| 2024-06-30 | 365.91K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 1.22M shares 10-Q · filed 2024-08-12 | 2.14M shares derived: sum of 3 quarters · filed 2024-08-12 | 2.30M shares derived: sum of 4 quarters · filed 2024-08-12 | |
| 2024-03-31 | 849.96K shares 10-Q · filed 2024-05-02 | 1.77M shares derived: sum of 2 quarters · filed 2024-05-02 | 1.93M shares derived: sum of 3 quarters · filed 2024-05-02 | 2.33M shares derived: sum of 4 quarters · filed 2024-05-02 | |
| 2023-12-31 | 923.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 1.08M shares derived: sum of 2 quarters · filed 2024-03-05 | 1.48M shares derived: sum of 3 quarters · filed 2024-03-05 | 1.69M shares 10-K · filed 2024-03-05 | |
| 2023-09-30 | 160.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | 556.90K shares derived: sum of 2 quarters · filed 2023-10-30 | 764.40K shares 10-Q · filed 2023-10-30 | 2.18M shares derived: sum of 4 quarters · filed 2023-10-30 | |
| 2023-06-30 | 396.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 603.90K shares 10-Q · filed 2023-08-03 | 2.02M shares derived: sum of 3 quarters · filed 2023-08-03 | 2.38M shares derived: sum of 4 quarters · filed 2023-08-03 | |
| 2023-03-31 | 207.50K shares 10-Q · filed 2023-05-11 | 1.63M shares derived: sum of 2 quarters · filed 2023-05-11 | 1.98M shares derived: sum of 3 quarters · filed 2023-05-11 | 2.30M shares derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-12-31 | 1.42M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 1.78M shares derived: sum of 2 quarters · filed 2023-03-02 | 2.09M shares derived: sum of 3 quarters · filed 2023-03-02 | 2.27M shares 10-K · filed 2023-03-02 | |
| 2022-09-30 | 355.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 672.18K shares derived: sum of 2 quarters · filed 2022-11-03 | 845.47K shares 10-Q · filed 2022-11-03 | 1.93M shares derived: sum of 4 quarters · filed 2022-11-03 | |
| 2022-06-30 | 316.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 490.07K shares 10-Q · filed 2022-08-04 | 1.57M shares derived: sum of 3 quarters · filed 2022-08-04 | 1.96M shares derived: sum of 4 quarters · filed 2022-08-04 | |
| 2022-03-31 | 173.29K shares 10-Q · filed 2022-05-02 | 1.25M shares derived: sum of 2 quarters · filed 2022-05-02 | 1.64M shares derived: sum of 3 quarters · filed 2022-05-02 | 2.05M shares derived: sum of 4 quarters · filed 2022-05-02 | |
| 2021-12-31 | 1.08M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 1.47M shares derived: sum of 2 quarters · filed 2022-03-10 | 1.88M shares derived: sum of 3 quarters · filed 2022-03-10 | 2.24M shares 10-K · filed 2022-03-10 | |
| 2021-09-30 | 389.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 799.18K shares derived: sum of 2 quarters · filed 2021-11-04 | 1.16M shares 10-Q · filed 2021-11-04 | 1.25M shares derived: sum of 4 quarters · filed 2021-11-04 | |
| 2021-06-30 | 409.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 770.98K shares 10-Q · filed 2021-08-05 | 856.57K shares derived: sum of 3 quarters · filed 2021-08-05 | ||
| 2021-03-31 | 361.00K shares 10-Q · filed 2021-05-06 | 446.60K shares derived: sum of 2 quarters · filed 2021-05-06 | |||
| 2020-12-31 | 85.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | 6.25M shares 10-K · filed 2021-03-04 | |||
| 2020-09-30 | 6.17M shares 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |